格隆汇12月11日丨康缘药业(600557.SH)公布，公司董事会于近日收到公司董事兼财务总监江锁成先 生、副总经理鲜飞鹏先生提交的辞任报告。江锁成先生因工作调整原因申请辞去董事兼战略委员会委 员、财务总监职务，辞去上述职务后，其仍继续在公司任职。鲜飞鹏先生因个人原因申请辞去副总经理 职务，其辞职后不再担任公司及控股子公司的任何职务。 ...

证券简称：康缘药业 证券代码：600557 公告编号：2025-040 江苏康缘药业股份有限公司 第八届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（简称"公司"）第八届董事会第二十二次会议通知 于 2025 年 12 月 1 日以书面文件、电话和电子邮件方式发出，会议于 2025 年 12 月 11 日在公司会议室以现场结合通讯方式按期召开。应出席会议董事 8 人，实际出席 会议董事 8 人。本次会议的召开符合《公司法》等法律法规以及《公司章程》的规 定。会议由副董事长王振中先生主持，会议以举手和通讯表决的方式审议通过以下 议案，并形成决议。 一、审议通过了《关于取消监事会并修改<公司章程>的议案》 根据《中华人民共和国公司法》、中国证监会《关于新<公司法>配套制度规则 实施相关过渡期安排》《上市公司章程指引（2025 年修订）》等相关法律法规、监 管制度的规定，结合公司实际情况，公司拟不再设置监事会，并修改《公司章程》， 删除与监事会、监事相关内容，由董事会审计委员 ...

Core Viewpoint - Kangyuan Pharmaceutical has successfully included its unique products, including Wenyang Jiedu Granules and Yunu Decoction Granules, as well as the first generic drug Sumatriptan Naproxen Sodium Tablets, in the National Medical Insurance Directory (2025 edition) [1] Group 1 - Wenyang Jiedu Granules, as a unique product, is recognized for its clinical efficacy in improving symptoms such as cough, fever, fatigue, and loss of appetite, along with good safety [1] - Yunu Decoction Granules, also a unique product, is classified as a Category 3.1 new traditional Chinese medicine, aimed at treating dental pain, periodontal disease, oral ulcers, diabetes, and early-stage diabetes [1] - Sumatriptan Naproxen Sodium Tablets are expected to provide a new treatment option for acute migraine [1] Group 2 - The inclusion of these new drug varieties in the National Medical Insurance Directory is anticipated to drive the company's market promotion and sales growth, enhance its R&D innovation and brand influence, and benefit a wide range of patients [1] - The company has established a rich product portfolio in the respiratory and infectious disease sector, including products like Heat Toxicity Ning Injection and Jinzhen Oral Liquid, which have shown significant clinical efficacy [2] - Despite a decline in sales due to weakened terminal demand in the first three quarters of 2025, the company is ramping up production to meet the recovering market demand in the fourth quarter [2] Group 3 - The company is advancing its pipeline of innovative biological drugs for treating obesity or overweight and type 2 diabetes, with the first subject enrollment for the innovative drug ZX2021 Injection completed in June 2025, showing weight loss effects [3] - The innovative drug ZX2010 Injection for type 2 diabetes and obesity has also commenced its second-phase clinical trials, with plans to enter the third phase in Q3 2026 [3] - The company is committed to progressing all its research pipelines according to clinical plans and aims for early market launch [3]

每经AI快讯，康缘药业（SH 600557，收盘价：15.24元）12月9日晚间发布公告称，截至本公告披露 日，董事兼总经理杨永春先生、董事高海鑫先生、董事陈学斌先生、副总经理刘权先生、副总经理王传 磊先生、副总经理潘宇先生以自有资金通过上海证券交易所交易系统以集中竞价交易方式累计增持股份 12万股，占公司总股本的0.0212%，累计增持金额人民币185.04万元，相关增持计划实施完毕。 2025年1至6月份，康缘药业的营业收入构成为：工业企业国内销售占比98.89%，其他业务占比1.11%。 截至发稿，康缘药业市值为86亿元。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 曾健辉） ...

证券代码：600557 证券简称：康缘药业 公告编号：2025-039 江苏康缘药业股份有限公司 关于部分董事、高级管理人员增持股份结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 江苏康缘药业股份有限公司（以下简称"公司"）于 2025 年 11 月 8 日披 露了公司《关于公司部分董事、高级管理人员自愿增持公司股份计划的公告》（公 告编号：2025-035），董事兼总经理杨永春先生、董事高海鑫先生、董事陈学斌 先生、副总经理刘权先生、副总经理王传磊先生、副总经理潘宇先生基于对公司 未来发展的信心以及对公司长期投资价值的认可，计划自 2025 年 11 月 10 日起 1 个月内，通过上海证券交易所交易系统以集中竞价的方式，以自有资金增持公 司股份数量合计不低于 12 万股。 截至本公告披露日，上述增持主体以自有资金通过上海证券交易所交易 系统以集中竞价交易方式累计增持股份 12 万股，占公司总股本的 0.0212%，累 计增持金额人民币 185.04 万元，本次增持计划实施完毕。 | 增持主体名称 ...

截至本公告披露日，上述增持主体以自有资金通过上海证券交易所交易系统以集中竞价交易方式累计增 持股份12万股，占公司总股本的0.0212%，累计增持金额人民币185.04万元，本次增持计划实施完毕。 格隆汇12月9日丨康缘药业(600557.SH)公布，公司于2025年11月8日披露了公司《关于公司部分董事、 高级管理人员自愿增持公司股份计划的公告》，董事兼总经理杨永春先生、董事高海鑫先生、董事陈学 斌先生、副总经理刘权先生、副总经理王传磊先生、副总经理潘宇先生基于对公司未来发展的信心以及 对公司长期投资价值的认可，计划自2025年11月10日起1个月内，通过上海证券交易所交易系统以集中 竞价的方式，以自有资金增持公司股份数量合计不低于12万股。 ...

康缘药业公告，公司董事兼总经理杨永春、董事高海鑫、董事陈学斌、副总经理刘权、副总经理王传 磊、副总经理潘宇基于对公司未来发展的信心及对公司长期投资价值的认可，计划自2025年11月10日起 1个月内，通过上海证券交易所交易系统以集中竞价方式增持公司股份，合计不低于12万股。截至本公 告披露日，上述增持主体累计增持股份12万股，占公司总股本的0.0212%，累计增持金额人民币185.04 万元，本次增持计划实施完毕。 ...

Group 1 - The company announced that its unique products, Wenyang Jiedu Granules and Yunu Jian Granules, have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) through negotiations [2] - The company is the first in the domestic market to have its generic drug, Sumatriptan and Naproxen Sodium Tablets, included in the same catalog [2]

Group 1 - The core announcement is that Kangyuan Pharmaceutical (600557.SH) has had its products included in the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 [1] - The company’s exclusive products, Wenyang Jiedu Granules and Yunu Decoction Granules, have been included in the catalog [1] - The first generic drug, Sumatriptan Nasal Spray, has also been successfully negotiated for inclusion in the National Basic Medical Insurance Drug Catalog for 2025 [1]

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) announced that its exclusive products, Wenyang Jiedu Granules and Yunu Decoction, along with the first domestic generic drug, Sumatriptan Naproxen Sodium Tablets, have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notification regarding the inclusion of specific drugs in the 2025 insurance catalog [1] - Kangyuan Pharmaceutical's products are now part of the National Basic Medical Insurance, which may enhance their market accessibility and sales potential [1] - The inclusion of the first domestic generic drug indicates a significant milestone for the company in the competitive pharmaceutical market [1]